Plain English Summary
Background and study aims:
Worm infections, especially schistosomiasis (a parasitic worm infection transmitted through contact with water) have important effects on human health. Schistosomiasis can cause liver disease and problems with the gut and bladder. It may also cause anaemia and poor growth, and poor performance at school. On the other hand there is evidence that worm infections may protect against allergy and asthma. The Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA) is a designed to weigh the benefits of intensive (versus standard) intervention against worms, including schistosomiasis, versus the disadvantages in terms of allergy-related disease outcomes, and to investigate how worms protect against allergy-related diseases.
Who can participate?
The inhabitants of fishing villages in the islands of Koome sub-county, Mukono District, Uganda.
What does the study involve?
The study will allocate 13 villages to standard intervention against worms (mass treatment for schistosomiasis, with praziquantel, once a year, and for other worms, with albendazole, twice a year) versus treatment with both drugs four times a year.
What are the possible benefits and risks of participating?
Participating villages are expected to benefit from regular treatment for worm infections. The treatments do have some side effects (for example praziquantel, which causes itching, rashes, dizziness and diarrhoea, especially in people with heavy worm infections) but the team will provide treatment for these side effects.
Where is the study run from?
The Uganda Virus Research Institute with collaboration between the Vector Control Division of the Ugandan Ministry of Health, the UK Medical Research Council Unit at the Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine.
When is study starting and how long is it expected to run for?
The initial study will start in September 2012, and the main study is expected to start in late October 2012 and to run for four years.
Who is funding the study?
Wellcome Trust (UK)
Who is the main contact?
Prof. Alison Elliott
Prof Alison Elliott
Medical Research Council/UVRI Uganda Research Unit on AIDS
Lake Victoria Island Intervention Study on Worms and Allergy-related diseases
The hygiene hypothesis proposes that exposure to infection protects against inflammatory conditions such as allergy and autoimmunity. It has been intensively studied in affluent countries but not in low-income settings. In Africa, where infections are still the predominant threat to human health and inflammatory diseases are just beginning to emerge, there is an immediate need to determine whether effective control of infectious pathogens will result in an epidemic of inflammatory diseases that the continent is ill-equipped to address. There is also a rich opportunity to investigate immunological and genetic interactions between pathogens and inflammatory diseases in the context of exposures that the immune system evolved to combat, and to make discoveries that can be harnessed for therapeutic interventions and global health benefits.
This project is therefore designed to address the hypothesis that chronic helminth infection protects against asthma, eczema and atopy, and that effective anthelminthic treatment programmes will result in increased rates of allergy in low income countries.
1. Uganda Virus Research Institute, 02/05/2012, ref: GC/127/12/05/03
2. Uganda National Council for Science and Technology, 23/05/2012, ref: HS1183
3. London School of Hygiene & Tropical Medicine, 28/05/2012, ref: 6187
Cluster-randomised intervention trial
Primary study design
Secondary study design
Cluster randomised trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Worm infections and their effects on general health and on allergy-related conditions
Standard intervention against helminths (as recommended by the Vector Control Division at the Ministry of Health) comprises single-dose albendazole (400 mg) given twice-yearly to all community members aged one year or above, and annual praziquantel treatment (at a dose of approximately 40 mg/kg, but estimated by a height pole) to all individuals whose height falls within the range on the height pole. This height range excludes pre-school children. This standard intervention will be compared with an intensive intervention comprising home-delivered, quarterly albendazole and praziquantel to all household members in the whole community, including preschool children.
Primary outcome measures
2. Atopy (assessed by allergen-specific serum IgE)
3. Atopy (assessed by skin prick test responses)
Secondary outcome measures
1. Eczema (visible flexural dermatitis)
2. Helminth infection prevalence
4. Height and weight z-scores
6. Vaccine responses
7. Cognitive function in children
Overall trial start date
Overall trial end date
Participant inclusion criteria
Fishing camp villages in Koome sub-county, Mukono District, Uganda, will be eligible for inclusion. All households in participating villages will be eligible for inclusion in the surveys. In selected and participating households, all household members, of all ages, will be eligible for inclusion in the survey.
Target number of participants
The study will have two main surveys, a baseline survey and an outcome survey. At each main survey we aim to recruit a total of 3250 people from approximately 910 households.
Participant exclusion criteria
1. Villages will be excluded if their Local Council leaders refuse permission for them to participate
2. Households where all members refuse to participate, or where all members are absent during the survey period
3. Does not meet inclusion criteria
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Medical Research Council/UVRI Uganda Research Unit on AIDS
Wellcome Trust (UK) ref: 095778
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
The main trial results are expected to be published in 2017.
IPD sharing plan
Fully anonymised participant- and cluster-level data will be made available from Emily Webb (email@example.com) on reasonable request.
Intention to publish date
Participant level data
Available on request
Results - basic reporting
- ISRCTN47196031_SAP_26Oct16.docx Uploaded 26/10/2016